Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy

Pediatric Infectious Disease Journal

Volumn 29, Issue 8, 2010, Pages 774-777

  Resino, Salvador ^a   Palladino, Claudia ^b,c   Lorente, Raquel ^b   Micheloud, Dariela ^a   Maria Bellón, Jose ^b   Larru, Beatriz ^b   Gutiérrez, Maria Dolores Gurbindo ^b,d   José, Maria Isabel De ^e   Polo, Rosa ^f   Muñoz Fernández, Maria Ángeles ^a,d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d CSIC   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f Ministerio de Sanidad   (Spain)

Author keywords

adipokines; adverse effects; antiretroviral therapy; lipids; protease inhibitor

Indexed keywords

ADIPONECTIN; LEPTIN; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; LOPINAVIR; PYRIMIDINONE DERIVATIVE; RITONAVIR;

ARTICLE; CD4 CD8 RATIO; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE MARKER; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPID BLOOD LEVEL; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SPAIN; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; COMPLICATION; HIV ASSOCIATED LIPODYSTROPHY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFANT; PRESCHOOL CHILD; PROCEDURES; PROSPECTIVE STUDY;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INFANT; LEPTIN; LOPINAVIR; PROSPECTIVE STUDIES; PYRIMIDINONES; RITONAVIR;

EID: 77955175937     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181db741b     Document Type: Article

References (25)

1. Resino S, Resino R, Bellon JM, et al. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Clin Infect Dis. 2006;43:243-252.
2. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr. 2005;40:161-168.
3. Guillen S, Ramos JT, Resino R, et al. Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J. 2007;26: 334-338.
4. Dzwonek AB, Lawson MS, Cole TJ, et al. Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;43:121-123.
5. Resino S, Bellon JM, Ramos JT, et al. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study. J Antimicrob Chemother. 2004;54:921-931.
6. Larru B, Resino S, Bellon JM, et al. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIVinfected children. J Antimicrob Chemother. 2008;61:183-190.
7. Kosalaraksa P, Bunupuradah T, Engchanil C, et al. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Pediatr Infect Dis J. 2008;27:623-628.
8. Taylor P, Worrell C, Steinberg SM, et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virusinfected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics. 2004;114:e235-e242.
9. Wohl DA, McComsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis. 2006;43:645-653.
10. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care. 2007;30:113-119.
11. Krause JC, Toye MP, Stechenberg BW, et al. HIV-associated lipodystrophy in children. Pediatr Endocrinol Rev. 2005;3:45-51.
12. Antuna-Puente B, Feve B, Fellahi S, et al. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008;34:2-11.
13. Garcia-Merino I, de Las Cuevas N, Jimenez JL, et al. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology. 2009;6:27.
14. Sharland M, Gibb D, Giaquinto C. Current evidence for the use of paediatric antiretroviral therapy-a PENTA analysis. Paediatric European Network for the Treatment of AIDS Steering Committee. Eur J Pediatr. 2000;159:649-656.
15. Hartman K, Verweel G, de Groot R, et al. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J. 2006;25:427-431.
16. Sweeney LL, Brennan AM, Mantzoros CS. The role of adipokines in relation to HIV lipodystrophy. AIDS. 2007;21:895-904.
17. Verkauskiene R, Dollfus C, Levine M, et al. Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome. Pediatr Res. 2006;60:225-230.
18. Kim RJ, Carlow DC, Rutstein JH, et al. Hypoadiponectinemia, dyslipidemia, and impaired growth in children with HIV-associated facial lipoatrophy. J Pediatr Endocrinol Metab. 2007;20:65-74.
19. Papaevangelou V, Papassotiriou I, Vounatsou M, et al. Changes in leptin serum levels in HIV-infected children receiving highly active antiretroviral therapy. Scand J Clin Lab Invest. 2007;67:291-296.
20. Resino S, Bellón JM, Ramos JT, et al. Salvage antiretroviral therapy in HIV-infected children: advantages of lopinavir-ritonavir. Pediatr Infect Dis J. 2004;23:923-930.
21. Ene L, Goetghebuer T, Hainaut M, et al. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr. 2007;166: 13-21.
22. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288-1295.
23. Cianflone K, Zakarian R, Stanculescu C, et al. Protease inhibitor effects on triglyceride synthesis and adipokine secretion in human omental and subcutaneous adipose tissue. Antivir Ther. 2006;11:681-691.
24. Rosicka M, Krsek M, Matoulek M, et al. Serum ghrelin levels in obese patients: the relationship to serum leptin levels and soluble leptin receptors levels. Physiol Res. 2003;52:61-66.
25. Tsiodras S, Mantzoros C. Leptin and adiponectin in the HIV associated metabolic syndrome: physiologic and therapeutic implications. Am J Infect Dis. 2006;2:141-152.